Market Research Blog – Page 9656 – New Product Development

Global Market Study on Biopharmaceutical Contract Manufacturing Demand: Strong Pipeline to Rapidly Surge Growth

Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some advantages offered by biopharmaceutical manufacturing companies. On the back of these factors, several large companies have outsourced their biopharmaceutical manufacturing operations. Biopharmaceutical contract manufacturing is highly preferred among biopharmaceutical companies with limited in-house production capacity.

Get Sample PDF: https://www.futuremarketinsights.com/reports/sample/rep-gb-2982

Pharmaceutical companies mainly focus on core areas of competence, and hence, do not prefer to take financial risks in the event of formulating the final dose of medicines. This is anticipated to accelerate the growth of the global biopharmaceutical contract manufacturing market during forecast period, estimated to be valued at US$ 18.7 Bn by 2029.

List of Key Players Covered in Biopharmaceutical Contract Manufacturing market are:

Catalent Inc.
Lonza Group Ag
Patheon N.V. (Thermo Fisher Scientific Inc.)
Abzena Plc.
Sandoz International GmbH (Novartis AG)
Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
AbbVie Contract Manufacturing (AbbVie Inc.)
Samsung Biologics Co. Ltd.
ProBioGen AG
Pfizer Centre Source Ltd (Pfizer Inc.)
Novasep
Biomeva GmbH
Kbi Biopharma Inc
Rentschler Biotechnologie GmbH
Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)

“Asia Pacific is gaining attention among manufacturers for biologics production at reduced manufacturing cost. Emerging regions offering greater profit margins are major focus points for biopharmaceutical contract manufacturing, globally.”

Browse Detailed Summary of Research Report with TOC: https://www.futuremarketinsights.com/reports/biopharmaceutical-contract-manufacturing-market

Key Takeaways of Biopharmaceutical Contract Manufacturing Market Study

Although microbial-based platforms are abundantly used for the production of pharmaceuticals, mammalian-based cell culture is expected to gain traction during the forecast period, owing to higher efficiency and increasing demand.
In terms of product type, monoclonal antibodies currently hold a larger share of the biopharmaceutical contract manufacturing market, due to their superior efficacy as well as increasing adoption for the treatment of chronic diseases.
North America is anticipated to be the most lucrative region in the global biopharmaceutical contract manufacturing market, offering growth opportunities to market players.
The commercial application of biopharmaceutical contract manufacturing is expected to contribute a higher share as compared to clinical application by the end of 2029.

Order a Complete Research Report: https://www.futuremarketinsights.com/checkout/2982

Regional Insights

The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period.

Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option.

China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the biopharmaceutical contract manufacturing market in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth.

By Region:

North America
Latin America
Western Europe
Eastern Europe
APEJ
Japan
Middle East and Africa (MEA)

Detailed Table of Content:

Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. Analysis and Recommendations

Market Introduction

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

Market Background

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

3.3. Regulatory Overview

Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Opportunity Assessment, 2022-2029
Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Platform

TOC continued..!

Speak to our Research Expert: https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-2982

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Farm Animal Drugs Market – Global Analysis, Size, Share, Growth, Trends and Forecast 2022-2032

According to a latest study by Future Market Insights (FMI), the global Farm Animal Drug Market is projected to grow at over 6% CAGR during the period 2017-2027. Increased production of anti-infectives and penetration of parasiticides production in Latin America is expected to offer growth opportunities to players in this market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2402

The market will continue to be influenced by a slew of macro- and micro-economic factors. Demand for contamination-free meat and proteins and alliances between producers and meat companies will continue to offer growth opportunities.

North America Farm Animal Drugs Market

In North America, the U.S. will continue to be account for the leading revenue share. In 2017, the revenue share of the U.S. is anticipated to reach 58%; however, during the forecast period, it will lose slight market share to Canada. Demand for farm animal drugs in North America will continue to be influenced by growing consumption of fresh meat and regulation by the FDA to limit use of antibiotics on farm animals. FMI projects the North America farm animal drugs market to grow at 7% CAGR during the forecast period 2017-2027.

By product type, anti-infective drugs and parasiticides (endo-parasiticides, ecto-parasiticides, and endectocides). Anti-infectives are not only the largest but also the fastest-growing segment product type segment. By 2027, the anti-infective product type segment is projected to grow at nearly 9% CAGR. By animal type, poultry is the largest segment in North America, whereas ruminants and swine hold significant revenue share.

FMI also offers market forecast and analysis on the basis of route of administration. The oral route of administering drugs remains the most prominent in North America, with revenues projected to grow at over 7% CAGR. The parenteral drug segment, on the other hand, is anticipated to grow at nearly 9% CAGR through 2027.

By distribution channel, veterinary hospitals are the largest segment in North America, accounting for nearly US$ 2 billion in revenues in 2017. This segment is projected to grow at nearly 8% through 2027.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2402

Western Europe Farm Animal Drugs Market

U.K. remains the largest market for farm animal drugs in Western Europe. The country accounts for over 40% revenue share of the market. FMI projects U.K. to remain the largest market for farm animal drugs in Western Europe throughout the forecast period. Germany and France are the other leading markets for farm animal drugs in Western Europe. Overall, the Western Europe farm animal drugs market is projected to reach US$ 2.83 billion revenues in 2027.

The key factors fuelling demand for farm animal drugs in Western Europe include focus on preventive measures against zoonotic diseases. Use of certain drugs for pain management is also a growing opportunity for manufacturers. As is the case in North America, the anti-infective product type segment is projected to grow at over 6% CAGR through 2027.

In addition to North America and Western Europe, the report also offers market forecast and analysis on Asia Pacific excluding Japan, Middle East & Africa, Latin America, and Japan.

Competitive Landscape

Key companies profiled in the report are Bayer AG, Boehringer Ingelheim GmbH, Zoetis, Inc., Ceva Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health (Sub. Eli Lilly), Merck Animal Health, Virbac SA, Vetoquinol SA, Intas Animal Health, Alembic Animal Health, Sequent Scientific, Hester Biosciences, Ashish Life Sciences, Ouro Fino Saude Animal (Ourofino), Zydus Animal Health (Sub. Cadila Healthcare Ltd), Phibro Animal Health Corporation, Nippon Zenyaku Kogyo Co., Ltd, Norbrook, Kyoritsu Seiyaku Corporation.

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-2402

Market segmentation

A good market segmentation always covers the vitals in that particular market to arrive at important decisions. In the case of the farm animal drugs market, an all-inclusive research segmentation can be seen.

Product Type

Anti-Infective
Parasiticides
- Endo-parasiticides
- Ecto-parasiticides
- Endectocides
Anti-inflammatory
Anesthetics
Analgesics
Hormones and related products
Others

Animal Type

Livestock Animals
- Ruminants
- Swine
- Poultry
Equine

Route of Administration

Oral
Parenteral
Topical
Others

Distribution Channel

Veterinary Hospitals
Veterinary Clinics
Pharmacies and Drug Stores
Others

About Future Market Insights (FMI)

Contact:

Oral Controlled Release Drug Delivery Technology Market to reach a valuation of about US$ 68.4 Bn by the end of 2032

Future Market Insights (FMI), in its report, projects the Global Oral Controlled Release Drug Delivery Technology Market to register an impressive expansion at 7.2% CAGR during the forecast period 2017 to 2027.

Request Sample Copy of Report @

https://www.futuremarketinsights.com/reports/sample/rep-gb-4400

The market will surpass revenues worth US$ 20,000 Mn in 2017, and is further estimated to reach nearly US$ 50,000 Mn by 2027-end.

Oral Solid Dosage Manufacturers in North America Enabled to Achieve Significant Bioavailability

FMI’s report estimates North America to remain the largest market for oral controlled release drug delivery technology, with sales estimated to reach nearly US$ 20,000 Mn by 2027-end.

Being preferred route of drug administration by physicians, demand for oral controlled release drug delivery technology has been witnessing a surge by end-users in North America.

In addition, recent advancements in drug delivery have enabled oral solid dosage manufacturers in North America to achieve significant bioavailability through adoption of novel drug delivery platforms.

This is further expected to drive demand for oral controlled release drug delivery technology in the region.

However, increasing research activities related to biologic molecules, and their dominance in treating oncology conditions, coupled with government investments in these research activities are expected to impede the market growth in North America.

In addition, formulation challenges such as juncture of market expectations for once-daily dosing, and growth of controlled release tablets which impart abuse resistance, incurred in oral controlled release drug delivery technology are expected to further curb growth of the market in this region.

Request a Complete TOC of this Report with figures @ https://www.futuremarketinsights.com/toc/rep-gb-4400

New Chemical Entities Resulting from High Throughput Screening to Drive Market Growth in Western Europe

Western Europe will register the fastest expansion in the global oral controlled release drug delivery technology market.

This growth is primarily attributed to a slew of new chemical entities resulting from high throughput screening, which have low solubility and bioavailability.

This has further led manufacturers in this region to invest in drug delivery methods with better clinical outcome.

Owing to cost-sensitiveness in Western European countries, technologies enhancing bioavailability will remain preferred drug delivery system. These factors are expected to drive growth of the market in this region.

However, most of the pharmaceutical companies in Western Europe have complex supply chain, which is either under-utilised or inefficient.

Complexity of supply chain is attributed to low flexibility and cost-effectiveness. In addition, shortening of effective patent life along with patent cliffs is a major challenge for oral solid dosage forms in this region.

Factors such as these are estimated to hinder growth of the market in Western Europe.

Dissolution-Controlled Release System to Remain Sought-After among Drug Release Technologies in the Market

By drug release technology, dissolution-controlled release system will remain sought-after in the market, followed by diffusion-controlled release system.

Majority of generic formulations available are in tablet dosage form and follow dissolution-controlled release mechanism. Revenues from sales of dissolution-controlled release system will surpass US$ 10,000 Mn in 2017.

Demand for hydrodynamically-balanced drug delivery system will remain sluggish in the market.

Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027.

Sales of semisolid/liquid/suspensions dosage form segment will register a comparatively lower CAGR than that of solid dosage forms in the market through 2027.

Feel free to ask your queries @

https://www.futuremarketinsights.com/ask-question/rep-gb-4400

Key market players identified in FMI’s report include

AstraZeneca Plc.,

Bristol-Myers Squibb Company,

Sun Pharmaceuticals Industries Ltd,

Abbott Laboratories,

Merck & Co. Inc.,

Novartis AG,

Pfizer Inc.,

Mylan N.V.,

Sanofi,

Hoffman-La-Roche Ltd.,

Johnson & Johnson Services, Inc.,

Vectura Group plc.,

GlaxoSmithKline plc.

Market Taxonomy

By Region

North America

Latin America

Western Europe

Eastern Europe

APEJ

Japan

MEA

By Drug Release System

Diffusion Controlled Release System

Dissolution Controlled Release System

Osmotically Controlled Release System

Dissolution & Diffusion Controlled Release System

Ion Exchange Resins Controlled Release

Hydro-dynamically Balanced Drug Delivery System

Others

By Dosage Form

Solid Dosage Forms
Semisolid
Liquid/Suspension

Buy Now@ https://www.futuremarketinsights.com/checkout/4400

About Future Market Insights (FMI)

Contact:

Dengue vaccines Increasing Research and Development Projects to Spell Growth of the Market

Increasing prevalence of dengue fever throughout the Asia-Pacific region has propelled the demand for effectual medicines and vaccines to overcome this viral disease. While some pharmaceutical companies are focusing on development of a cure to dengue, the rate of dengue in Asia-Pacific region in expanding robustly. According a report published by Future Market Insights (FMI), Asia-Pacific region will dominate in the dengue vaccines market during the forecast period (2017-2027). The region is estimated to procure largest revenue share with expansion at 17.4% CAGR throughout the assessment period.

Get Sample of this Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1763

Geographic Overview

Latin America is likely to remain the second largest market for dengue vaccines and it will procure valuation nearly US$ 290 Mn by the end of forecast period. The report also forecasts that more and more pharmaceutical companies will be partaking in the expansion of dengue vaccines market in foreseeable period. A French drugmaker, Sanofi S.A. is actively participated in the market currently, while medicines are being formulated by leading players such as GlaxoSmithKline plc, Vabiotech, Merck & Co. Inc., Butantan Institute, Panacea Biotech Ltd, Takeda Pharmaceutical Company Limited, and Biological E. Limited.

The government institutes are expected to remain the largest end-user of the dengue vaccines, according to the report. Dengue vaccines sales across government institutes will generate revenues nearly US$ 650 Mn by the end of 2027. Further, hospitals will retain its dominance, exhibiting double-digit CAGR throughout the forecast period. Sales of the sole of the vaccines, Dengvaxia, manufactured by Sanofi is boosting the growth of the market presently. Additionally, the factors influencing the growth of the market profiled in the report are discussed below.

Key Highlights of Dengue Vaccines Market Report

Other than the burdening occurrence of dengue in some countries, the economic turmoil in Latin America is estimated to influence growth of the global market at macroeconomic level.
Live attenuated vaccines are also produced and developed economically, thereby consoling vaccines market and patients.
Low availability of optimum diagnostic systems and lack of skilled professionals have led to cases, where dengue fever is being treated as undistinguished febrile disease.
The global market of dengue vaccines is likely to secure an opportunistic revolution when companies are likely to able to successfully develop effective vaccines for all age groups.

Overall, the global dengue vaccines market, which is currently valued nearly US$ 250 Mn, will increase rapidly to reach over US$ 1,250 Mn in terms of revenues, by the end of 2027.

Buy this Research Report for Professional and Technical Industry Insights: https://www.futuremarketinsights.com/checkout/1763

About Future Market Insights (FMI)

Contact:

Companion Animal Vaccines Market Report 2022: Consistent Levels of R&D Driving Sector Growth

Remarkable increase in the companion animal ownership and strong growth of development of the veterinary healthcare infrastructure collectively push the sales of companion animal vaccines in global market.

Request Sample Copy of Report @

https://www.futuremarketinsights.com/reports/sample/rep-gb-1427

Surpassing the revenues worth US$ 2.5 Bn in 2021, global Companion Animal Vaccines Market is projected to exhibit a robust CAGR during 2022 – 2029.

Measurable rise in the zoonotic disease prevalence will remain a key factor fueling the demand for companion animal vaccines and drugs.

FDA approvals for novel and innovative companion animal vaccines continue to present potential growth opportunities to R&D of companion animal vaccines.

For instance, Zoetis received regulatory approval for ProHeart, used for prevention of heartworm diseases caused by Dirofilaria immitis in dogs.

Key Takeaways – Companion Animal Vaccines Market Study

Attenuated live vaccines currently account for more than a third of total market value, and will continue to witness a healthy CAGR through 2029. This demand growth is attributed to their improved effectivity and enhanced long-term preventive action.
North America is witnessing lucrative market growth compared to other regions attributed to increase in the adoption rate of companion animals, increase in veterinary healthcare expenditure, and increasing awareness about pet health.
Veterinary animal hospitals and clinics offering better service support for animal care are expected to have significant market share during the forecast period
As large number of people are in close contact with canine animals as a preference for companion animal, demand will be prominent among canine species.

Increasing R&D Investments to Widen Market Growth Prospects

Elanco, Ceva Sante Animale, Boehringer Ingelheim are among the leading market players in the companion animal vaccines market.

These manufacturers continue to dominate the market landscape of companion animal vaccines by investing heavily in R&D activities to develop and launch therapeutic vaccines for prevention and treatment of various animal diseases.

Surge in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the animal vaccines market growth.

For instance, in August 2018, Elanco invested two-thirds of the budget for food‐animal unit to develop vaccines and reduce the use of antibiotics.

Moreover, rise in demand for animal vaccines led to the development of multiple new vaccines.

For instance, Cevac IBron a new vaccine was launched by Ceva in February 2017 for prevention against infectious bronchitis virus (IBV) in animals.

Ask from the Market Research Expert @

https://www.futuremarketinsights.com/ask-question/rep-gb-1427

Know More About Companion Animal Vaccines Market Report

Future Market Insight brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2029.

The global companion animal vaccines is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights of the companion animal vaccines market on basis of product type (attenuated live vaccines, conjugated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines), species type (canine, avian, feline) and distribution channel (companion animal hospitals, companion animal hospitals, companion animal research institutes) across seven major regions.

Segmented

Product

Attenuated Live Vaccines
Conjugate Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
DNA Vaccines
Recombinant Vaccines

Species

Canine
Avian
Feline

Distribution Channel

Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institutes
Retail Pharmacies

Buy Now@ https://www.futuremarketinsights.com/checkout/1427

About Future Market Insights (FMI)

Contact:

Widefield Imaging Systems Market Business Summation, Industry Examination, Standpoint

According to a recent study by Future Market Insights (FMI), the global widefield imaging systems market is expected to register high growth during the forecast period. The market is expected to grow from US$ 556.9 Mn in 2021 to over US$ 1.3 Bn by 2031. It is expected register a CAGR of around 8.6% over the forecast period (2021-2031).

Get Sample of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1732

Significant rise in cases of diabetic retinopathy is expected to propel the growth of the global widefield imaging systems market during the forecast period. Widefield retinal imaging includes imaging of peripheral retina that is the main site of various ocular diseases.

Widefield imaging aids in diagnosis of peripheral retina diseases. Occurrence of eye diseases like vision impairment is rising among teenagers. Increasing usage of mobile phones and computers results into digital eye strain, and is mainly responsible for visual impairment among teenagers.

As per the Centers for Disease Control and Prevention, in 2020, approximately 6.8% of children below 18 years have been detected with vision and eye condition in the United States.

Increasing technological awareness and high focus on healthcare innovations are some of the factors encouraging the adoption of these instruments. Additionally, certain companies, as a part of their product strategies, are launching technologically advanced equipment, to consolidate larger market share.

Government funding towards expansion of healthcare infrastructure will support growth in developing countries. Moreover, corporate contracts based on rent-to-own model is a feasible option in emerging economies such as India and Brazil which could create significant opportunities for manufacturers of widefield imaging systems to capitalize on.

Key Takeaways From Widefield Imaging Systems Market Study

Widefield imaging instruments will account for 80% sales in the global market in 2021 of.
Diabetic retinopathy is the most rapidly growing segment by indication, accounting for nearly 1/3rd of the market share.
Standalone type of modality will remain highly preferred, contributing 56.4% towards overall sales in the market in 2021.
Demand in hospitals accounted for 40.2% of widefield imaging systems sales in 2020.
North America will remain the dominant widefield imaging systems market globally, exhibiting a CAGR of nearly 8.6% between 2021 and 2031.

Contact our Market Research Specialist@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1732

Who Is Winning?

The key market players covered by FMI include Heidelberg Engineering GmbH, Visunex Medical Systems, Inc., Carl Zeiss Meditec AG, Clarity Medical Systems, Inc. Optos plc, and Centervue SpA.

The leading manufacturers of widefield imaging systems are focusing on new product development and launch of advanced versions of existing devices. Their aim is primarily to expand their portfolio to gain competitive edge. For instance:

In March 2020, Heidelberg Engineering announced the reintroduction of its HRT3 Rostock Cornea Module (RCM) to offer in vivo corneal confocal microscopy in its anterior segment product portfolio, supporting cornea specialists worldwide to further improve patient care.

In August 2020, ZEISS announces new software for the IOLMaster® 700, with enhanced features and connectivity designed to improve the cataract surgeons’ workflow efficiency and support better outcomes for surgeons and patients.

Widefield Imaging Systems Market By Category

By Component:

Instrument
Software
- Image Viewing Software
- Data Analysis and Interpretation Software

By Indication:

Diabetic Retinopathy
Retinopathy of Prematurity
Pediatric Retinal Diseases
Retinal Vein Occlusion
Ocular Oncology
Uveitis
Chorioretinal Disease
Glaucoma
Others

Request Customization of the report @ https://www.futuremarketinsights.com/customization-available/rep-gb-1732

By Modality:

Standalone
Portable

By End User:

Specialty Clinics
Hospitals
Ambulatory Surgical Centers

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)

About Future Market Insights (FMI)

Contact:

Radiotherapy Positioning Devices Market Insights, New Innovations, Research and Growth Factor till 2027

With 1000+ market research reports and 1 billion+ data points, Future Market Insights (FMI) serves each and every requirement of the clients operating in the global healthcare, pharmaceuticals, and medical device industries. FMI deploys digital intelligence solutions to offer compelling insights to report buyers that help them in overcoming market challenges, especially at the time of a crisis. Our dedicated team of professionals performs an extensive survey for gathering accurate information associated with the market.

Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-5898

FMI, in its upcoming business report, elaborates the historical and current scenario of the global Radiotherapy Positioning Devices market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Radiotherapy Positioning Devices market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Radiotherapy Positioning Devices Market

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Radiotherapy Positioning Devices market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Radiotherapy Positioning Devices market.

Following government’s measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the Radiotherapy Positioning Devices market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

Why Choose Future Market Insights

Serving domestic and international clients 24/7
Prompt and efficient customer service
Data collected from reliable primary and secondary sources
Highly trained and experienced team of research analysts
Seamless delivery of tailor-made market research reports

Discounted prices for new customers! Offer expires soon!

Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-5898

Radiotherapy Positioning Devices Market: Segmentation

Valuable information covered in the FMI’s Radiotherapy Positioning Devices market report has been segregated into key segments and sub-segments.

Based on Product Type, the Radiotherapy Positioning Devices market is divided into following:

Head, Neck and Brain immobilization Device
Thorax and Breast Immobilization Device
Pelvic Immobilization Devices
Others

Based on the End User, the global Radiotherapy Positioning Devices market is divided into following:

Hospitals
Ambulatory surgical centers
Cancer Research Institutes
Others

Radiotherapy Positioning Devices Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Radiotherapy Positioning Devices market. Competitive information detailed in the Radiotherapy Positioning Devices market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Radiotherapy Positioning Devices market report.

Key players covered in the report include:

CIVCO Radiotherapy, Elekta AB, Bionix Radiation Therapy, ORFIT INDUSTRIES NV, Qfix, VERTEC LTD Klarity Medical Products, Varian Medical Systems, Inc. and others.

Important Questions Answered in the Radiotherapy Positioning Devices Market Report

Which end user remains the top revenue contributor in different regional markets?
At what rate has the global Radiotherapy Positioning Devices market been expanding during the forecast period?
How will the global Radiotherapy Positioning Devices market look like by the end of the forecast period?
What innovative strategies are adopted by Radiotherapy Positioning Devices market players to stay ahead of the pack?
What are the restraints affecting the growth of the global Radiotherapy Positioning Devices market?

Buy Now@ https://www.futuremarketinsights.com/checkout/5898

Key Offerings of the Report

Growth Drivers and Opportunities: Comprehensive analysis on growth-driving factors and opportunities for market players in different regional markets
Recent Trends and Forecasts: Detailed assessment on the latest trends, technological developments, and forecasts for a 5-year or 10-year period.
Segmental Analysis: Extensive analysis on each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis
Regional Market Forecast: Thorough analysis of each regional market to arm stakeholders with necessary information to take critical decisions
Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Radiotherapy Positioning Devices market

About Future Market Insights (FMI)

Contact:

Ultrasonic Homogenizers Market Insights on Emerging Scope Prophesy | Future Market Insights

Ultrasonic Homogenizer has widely used in various industry and research areas which can act as driving force for the Ultrasonic Homogenizers Market. Technology advancement and expansion of dairy and food industry are the major driving force for ultrasonic homogenizers market. Maintenance of the ultrasonic homogenizer can be the restraints for the Ultrasonic Homogenizers market.

Get Sample Free Sample of this Premium Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4396

Ultrasonic Homogenizers Market Overview

The Ultrasonic Homogenizers one of the most widely used devices which are used to break down cell barriers, de-gas solutions sample preparation, cell lysing, disaggregation, homogenization, particle size reduction, soil testing, acceleration of chemical reactions, defoaming, atomization and many more uses.

Ultrasonic processors are extremely versatile and can safely process a variety of organic and inorganic materials in a range of volumes. Ultrasonic homogenizer also requires ensuring dissolution or the production of the micro particle to enhance its reactivity.

The substantial intensity of ultrasound and high ultrasonic vibration amplitudes are the basic principle of ultrasonic homogenizers. The market of Ultrasonic Homogenizers grows rapidly in chemical, biotechnology, nanotechnology, pharmaceuticals. The extensive use of ultrasonic homogenizer in dairy & food industry and wide use of ultrasonic homogenizer in chemical processing industry raise ultrasonic homogenizer market growth. The rapid heavy demand of ultrasonic homogenizer enhances the revenue growth of ultrasonic homogenizers market.Development in technology and increasing no of research institute assist the market growth for forecasted period.

By modality, Ultrasonic Homogenizers can be categorized into bench-top and hand-held. Bench-top category shares the majority of the ultrasonic homogenizer market. By Application, the global Ultrasonic Homogenizers market is segmented into dairy and food industry, chemical industry, pharmaceuticals industry, biotech laboratories and research laboratories whereas Ultrasonic Homogenizers consumption in dairy and food industry dominated over another sector.

Based on geography, the ultrasonic homogenizers market is segmented into North America, Europe, Latin America, Asia-Pacific and the Middle East and Africa. North America dominates the global Ultrasonic Homogenizers market followed by Europe However; the Asia-Pacific is expected to blow the Ultrasonic Homogenizers market globally.

Talk to Analyst: https://www.futuremarketinsights.com/ask-question/rep-gb-4396

Ultrasonic Homogenizers Market: Region-wise Outlook

By region, Global Ultrasonic Homogenizers market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, APEJ(Asia-Pacific Excluding Japan), Japan and Middle East & Africa. North America followed by Europe will continue to dominate the global Ultrasonic Homogenizers market attributed to growing number of food and dairy industry and research laboratories.

Furthermore, the newly developed technology in the ultrasonic homogenizer is also expected to result in higher demand for Ultrasonic Homogenizers market globally over the forecast period. Asia Pacific is expected to be the emerging region in the global Ultrasonic Homogenizers market.

Ultrasonic Homogenizers Market: Key Market Participants

The key players in the Ultrasonic Homogenizers market are BANDELIN electronic GmbH & Co. KG Hielscher Ultrasonics GmbH, BioLogics Inc. OMNI International, Pro Scientific INC., Sonic Corporation, Topas GmbH, etc. some Companies are involved in R&D to exploit maximum revenue potential in the global Ultrasonic Homogenizers market.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Buy this Report Now: https://www.futuremarketinsights.com/checkout/4396

Ultrasonic Homogenizers Market: Segmentation

The global market for Ultrasonic Homogenizers segmented by modality, application, and geography:

Segmented by Modality

Bench-top
Hand-held

Segmented by Application

Dairy and food industry
Chemical industry
Biotech Laboratories
Pharmaceuticals industry
Research laboratories

About Future Market Insights (FMI)

Contact:

Upstream Bioprocessing Equipment Market Trends, Business Overview, Industry Growth, and Forecast 2022-2026

Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2016

FMI, in its upcoming business report, elaborates the historical and current scenario of the global Upstream Bioprocessing Equipment market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Upstream Bioprocessing Equipment market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Upstream Bioprocessing Equipment Market

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Upstream Bioprocessing Equipment market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Upstream Bioprocessing Equipment market.

The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the Upstream Bioprocessing Equipment market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

Why Choose Future Market Insights

Serving domestic and international clients 24/7
Prompt and efficient customer service
Data collected from reliable primary and secondary sources
Highly trained and experienced team of research analysts
Seamless delivery of tailor-made market research reports

Discounted prices for new customers! Offer expires soon!

Contact our Market Research Specialist@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-2016

Upstream Bioprocessing Equipment Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Upstream Bioprocessing Equipment market. Competitive information detailed in the Upstream Bioprocessing Equipment market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Upstream Bioprocessing Equipment market report.

Key players covered in the report include:

GE Healthcare, Merck KGaA, Boehringer Ingelheim Pharma GmbH & Co.KG, Thermo Fisher Scientific, BiOZEEN and Katalyst Bio Engineering

Important Questions Answered in the Upstream Bioprocessing Equipment Market Report

Which end user remains the top revenue contributor in different regional markets?
At what rate has the global Upstream Bioprocessing Equipment market been expanding during the forecast period?
How will the global Upstream Bioprocessing Equipment market look like by the end of the forecast period?
What innovative strategies are adopted by Upstream Bioprocessing Equipment market players to stay ahead of the pack?
What are the restraints affecting the growth of the global Upstream Bioprocessing Equipment market?

Buy Now@ https://www.futuremarketinsights.com/checkout/2016

Key Offerings of the Report

Growth Drivers and Opportunities: Comprehensive analysis on growth-driving factors and opportunities for market players in different regional markets
Recent Trends and Forecasts: Detailed assessment on the latest trends, technological developments, and forecasts for a 5-year or 10-year period.
Segmental Analysis: Extensive analysis on each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis
Regional Market Forecast: Thorough analysis of each regional market to arm stakeholders with necessary information to take critical decisions
Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Upstream Bioprocessing Equipment market

About Future Market Insights (FMI)

Contact:

Microfluidics Market sales revenue expected to grow at 11.1% CAGR over the forecast period 2022-2031

According to a recent study by Future Market Insights (FMI), the global Microfluidics Market is expected to witness high growth during the forecast period. The market is expected to grow from US$ 5.9 Bn in 2021 to over US$ 17.8 Bn by 2031. This reflects a cumulative CAGR of around 11.1% over the forecast period (2022-2031).

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-398

The flow of liquids through various microscopic channels or mediums such as nozzles, pumps or chips is based on a technology known as microfluidics. The products based on such technology can control and direct the fluids at the lowest dimensions which could range from ten to hundreds of micrometers.

Microfluidics helps facilitate many assays concurrently. Thus, increasing the throughput where a good level of spatiotemporal control is possible. This reduces the consumption and cost of precious fluids, chemical and biological assays. Numerous applications utilizes microfluidics based technology such as clinical diagnostics, analytical testing, point-of-care testing and drug delivery. Genomics, proteomics and cell-based analysis uses microfluidics technology-based instruments and chips during analytical testing.

List of Key Players Covered in Microfluidics Market are:

Thermo Fisher Scientific Inc
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Bio-Rad Laboratories Inc.
Qiagen NV
SCHOTT AG
thinXXS Microtechnology

Microfluidics systems provides features such as ease of automation, reduction in the overall consumption of sample and reagents while reducing the analysis time. Thus, it can be considered as an attractive solution for various assays like chemical and biological assay. The system also allows to conduct assays parallel, thus decreasing the cost of the assays and time.

Microfluidics in 3D cell culture has recently enabled the development of microenvironments that facilitate differentiation of tissues and can also replicate the interface between 2 tissues. It can further facilitate spatiotemporal chemical gradients, as well as mechanical micro – environment of living organs. There is an ever-increasing demand for microfluidic lab-on-chip technology in the biomedical, pharmaceutical industries as well in anti-terrorism, environmental, food and military applications. To further add to this, the development of consumers, environmental and security markets, the speed, portability, availability and low costs of miniaturized biosensors have huge commercial potential.

Strategic collaborations among key players drive the microfluidics market to develop novel microfluidic platforms for drug discovery, portable diagnostic devices and others. The collaboration space is dominated by the players who have a strong product portfolio and patented technologies dedicated to clinical research and in-vitro diagnostics applications along with the local GMP certified manufacturing facilities.

In order to overcome difficulties associated with the fabrication included into the microfluidics devices, many companies are substituting the mixers in these devices with the bubbles at large. This can be the opportunity to improve the efficiency of the microfluidics devices creating a huge opportunity in the market.

Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-398

Key Takeaways from Microfluidics Study

The ceramics segment is anticipated to hold the maximum share of 39.9% in 2022, expanding at 13.0% CAGR during the forecast period. Ceramics’ superior chemical resistivity, flexibility, and strength make them ideal for producing microfluidics devices, as seen by their significant market share.
The point of care testing segment is projected to account for 32.6% of the total market share in 2022 by application. In the fields of genomics and proteomics, point-of-care testing devices offer a lot of potential. These devices, for example, aid in the identification of the DNA of bacteria that cause various diseases and are also employed in protein analysis.
In-vitro diagnostics and life science research together hold over 53% of the market in 2022 and this trend is expected to continue during the forecast period as well. The growing number of experiment carried out in life science research using microfluidics is rising. This is propelling the sector forward. Aside from that, with increasing diseases, is increasing the in-vitro diagnostics demand.
North America is expected to account for about 25.4% of the global microfluidics market. The high frequency and growth in incidence of various diseases, and government funding for the research and clinical testing by various institutions in the North America will assist market expansion.

Who is winning?

The key market players covered by FMI include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Abbott Laboratories, Bio-Rad Laboratories, Inc., Qiagen NV, SCHOTT AG and thinXXS Microtechnology.

Some of the leading manufacturers of the microfluidics market are focusing on the development of advanced and cost-effective products and undertaking acquisitions to increase global presence.

In October 2021, Thermo Fisher Scientific Charts Digital PCR expansion after Combinati acquisition.
In November 2019, MicroMedicine, Inc., launched the Sorterra Cell Isolation System, an automated, microfluidics-based cell isolation technology at the Society for Immunotherapy of Cancer (SITC) Meeting.

Browse Detailed Summary of Research Report with TOC @ https://www.futuremarketinsights.com/reports/microfluidics-market

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global microfluidics market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on microfluidics market segment based on material (polymer {polyvinyl chloride (PVC) non-polyvinyl chloride}, glass, silicon, metal and ceramics), application (point of care testing, clinical diagnostics, drug delivery and analytical testing {genomics, proteomics, cell based analysis and others}), and industry (pharmaceuticals, in-vitro diagnostics, environmental research, life science research, clinical diagnostics) across seven major regions.

Order a Complete Research Report @ https://www.futuremarketinsights.com/checkout/398

About Future Market Insights (FMI)

Contact: